IIM
VRDN icon

INTECH Investment Management’s Viridian Therapeutics VRDN Stock Holding History

INTECH Investment Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$522K Sell
28,413
-16,770
-37% -$270K ﹤0.01% 1328
2026
Q1 		$884K Buy
45,183
+11,057
+32% +$328K 0.01% 1069
2025
Q4 		$1.06M Hold
34,126
– – 0.01% 1102
2025
Q3 		$736K Sell
34,126
-16,542
-33% -$298K 0.01% 1361
2025
Q2 		$708K Sell
50,668
-10,960
-18% -$149K 0.01% 1404
2025
Q1 		$831K Buy
61,628
+22,053
+56% +$376K 0.01% 1314
2024
Q4 		$759K Buy
39,575
+21,009
+113% +$457K 0.01% 1318
2024
Q3 		$422K Buy
+18,566
New +$304K ﹤0.01% 1321

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

INTECH Investment Management's VRDN Position: Q2 2026 in Review

INTECH Investment Management reduced its Viridian Therapeutics (VRDN) stake by 37% in Q2 2026, selling an estimated $270K and leaving 28,413 shares worth $522K. The position accounts for ﹤0.01% of the portfolio, ranked #1328.

INTECH Investment Management first reported a position in VRDN in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.06M in Q4 2025. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • INTECH Investment Management held 28,413 shares of Viridian Therapeutics worth $522K as of Q2 2026.
  • INTECH Investment Management sold 16,770 Viridian Therapeutics shares in Q2 2026, an estimated $270K.
  • Viridian Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1328 holding.
  • INTECH Investment Management first reported a position in Viridian Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • INTECH Investment Management's Viridian Therapeutics position peaked at $1.06M in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.